Citigroup
NRIX icon

Citigroup’s Nurix Therapeutics NRIX Stock Holding History

Citigroup’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.45M Sell
389,384
-88,026
-18% -$1.5M ﹤0.01% 1664
2026
Q1 		$7.4M Buy
477,410
+306,308
+179% +$5.08M ﹤0.01% 1660
2025
Q4 		$3.25M Buy
171,102
+163,735
+2,223% +$2.35M ﹤0.01% 2325
2025
Q3 		$68.1K Sell
7,367
-36,360
-83% -$378K ﹤0.01% 4390
2025
Q2 		$498K Sell
43,727
-96,739
-69% -$1.05M ﹤0.01% 3630
2025
Q1 		$1.67M Buy
140,466
+33,116
+31% +$554K ﹤0.01% 2865
2024
Q4 		$2.02M Buy
107,350
+57,757
+116% +$1.32M ﹤0.01% 2809
2024
Q3 		$1.11M Buy
49,593
+22,171
+81% +$502K ﹤0.01% 3183
2024
Q2 		$572K Sell
27,422
-157,358
-85% -$2.45M ﹤0.01% 3305
2024
Q1 		$2.72M Buy
184,780
+169,635
+1,120% +$1.82M ﹤0.01% 2180
2023
Q4 		$156K Sell
15,145
-27,055
-64% -$185K ﹤0.01% 4030
2023
Q3 		$332K Sell
42,200
-4,760
-10% -$43.5K ﹤0.01% 3357
2023
Q2 		$469K Sell
46,960
-66,144
-58% -$675K ﹤0.01% 3421
2023
Q1 		$1M Buy
113,104
+39,508
+54% +$412K ﹤0.01% 2555
2022
Q4 		$808K Sell
73,596
-46,922
-39% -$566K ﹤0.01% 2813
2022
Q3 		$1.57M Buy
120,518
+45,253
+60% +$716K ﹤0.01% 2340
2022
Q2 		$954K Buy
75,265
+50,085
+199% +$568K ﹤0.01% 2701
2022
Q1 		$353K Sell
25,180
-51,431
-67% -$913K ﹤0.01% 3735
2021
Q4 		$2.22M Sell
76,611
-44,041
-37% -$1.34M ﹤0.01% 2546
2021
Q3 		$3.62M Sell
120,652
-1,859
-2% -$57.4K ﹤0.01% 2032
2021
Q2 		$3.25M Buy
122,511
+37,755
+45% +$1.11M ﹤0.01% 2275
2021
Q1 		$2.63M Buy
84,756
+81,242
+2,312% +$3.07M ﹤0.01% 2300
2020
Q4 		$116K Buy
3,514
+2,981
+559% +$98.8K ﹤0.01% 5422
2020
Q3 		$19K Buy
+533
New +$13.4K ﹤0.01% 6240

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citigroup's NRIX Position: Q2 2026 in Review

Citigroup reduced its Nurix Therapeutics (NRIX) stake by 18% in Q2 2026, selling an estimated $1.5M and leaving 389,384 shares worth $9.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1664.

Citigroup first reported a position in NRIX in Q3 2020 and has held it in 24 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Citigroup held 389,384 shares of Nurix Therapeutics worth $9.45M as of Q2 2026.
  • Citigroup sold 88,026 Nurix Therapeutics shares in Q2 2026, an estimated $1.5M.
  • Nurix Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1664 holding.
  • Citigroup first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.